Publications by authors named "Manjula Basappa"

Claim this Profile
I
Immune correlates analysis of antibody responses against SARS-CoV-2 variants in the ENSEMBLE vaccine efficacy trial.
Alex Luedtke, Youyi Fong, Lars van der Laan, Fei Heng, Ying Huang, Manjula Basappa

iScience· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid loss of activity but not serum concentration in a passive infusion clinical trial of an HIV neutralizing antibody.
Sharana Mahomed, Nonhlanhla N Mkhize, Leonid A Serebryannyy, Tandile Hermanus, Prudence Kgagudi, Manjula Basappa

medRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection.
Myra Happe, Rebecca M Lynch, Carl J Fichtenbaum, Sonya L Heath, Susan L Koletar, Manjula Basappa

JCI Insight· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.
Lindsay N Carpp, Ollivier Hyrien, Youyi Fong, David Benkeser, Sanne Roels, Manjula Basappa

Nat Commun· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.
Joseph P Casazza, Amelia R Hofstetter, Pamela J M Costner, LaSonji A Holman, Cynthia S Hendel, Manjula Basappa

NPJ Vaccines· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Betty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Prossy Naluyima, Manjula Basappa

Lancet Infect Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.
Kirsten E Lyke, Andrea A Berry, Kaitlin Mason, Azza H Idris, Mark O'Callahan, Manjula Basappa

Lancet Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
Melinda J Hamer, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Christine Lee, Manjula Basappa

Lancet· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.
Youyi Fong, Adrian B McDermott, David Benkeser, Sanne Roels, Daniel J Stieh, Manjula Basappa

Nat Microbiol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial.
Youyi Fong, Adrian B McDermott, David Benkeser, Sanne Roels, Daniel J Stieh, Manjula Basappa

medRxiv· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron.
Matthew Gagne, Juan I Moliva, Kathryn E Foulds, Shayne F Andrew, Barbara J Flynn, Manjula Basappa

Cell· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Monoclonal Antibody for Malaria Prevention.
Martin R Gaudinski, Nina M Berkowitz, Azza H Idris, Emily E Coates, LaSonji A Holman, Manjula Basappa

N Engl J Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2.
Abdelilah Majdoubi, Christina Michalski, Sarah E O'Connell, Sarah Dada, Sandeep Narpala, Manjula Basappa

JCI Insight· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base.
Angela R Corrigan, Hongying Duan, Cheng Cheng, Christopher A Gonelli, Li Ou, Manjula Basappa

Cell Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody reactivity to SARS-CoV-2 is common in unexposed adults and infants under 6 months.
Abdelilah Majdoubi, Christina Michalski, Sarah E O'Connell, Sarah Dada, Sandeep Narpala, Manjula Basappa

medRxiv· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis